Already in partnership with Novartis since 2003 in the area of hypertension, with the co-marketing in France of Nisis and Nisisco, Ipsen’s new agreement strengthens the commitment of its French teams to the management of cardiovascular risk factors.
Christophe Jean, COO of the Ipsen Group, said: “After the success of Nisis and Nisisco, we are delighted to extend our collaboration with Novartis Pharma, and to be able to offer patients and physicians a product with high added value in the field of cardiovascular medicine, which represents a major public health priority.
“This partnership will mean that this product will be available to Ipsen’s existing sales force in France, in line with our current strategy to optimize our primary care franchise.”